Gloria Biosciences

Gloria Biosciences is a dynamic biopharmaceutical company dedicated to developing and commercializing innovative immuno-oncology therapies. With a focus on patient-centered treatments, Gloria Biosciences is committed to bringing more effective treatment alternatives to cancer patients globally. The company has successfully launched zimberelimab ("Yutuo", "誉拓”), a novel, fully human anti-PD-1 mAb, for the treatment of relapsed or refractory classical Hodgkin’s lymphoma, demonstrating outstanding clinical results. Gloria Biosciences's commitment to innovation extends to exploring zimberelimab in multiple types of cancer and in combinations with other innovative drugs.

Gloria Biosciences operates from its headquarters in Shanghai, at the Primary address: The New Bund World Trade Center Phase 3, Tower A, #1602, Shanghai, CN. The company is actively developing a robust pipeline of monoclonal and bispecific antibodies, including LAG-3, to further enhance its offerings in the oncology space. With a seasoned team and a global perspective, Gloria Biosciences is poised to make significant contributions to cancer treatment.

Gloria Biosciences continues to strive for excellence in the pharmaceutical industry, focusing on cutting-edge research and development to meet the evolving needs of patients worldwide. We encourage the management team at Gloria Biosciences to create a customized and exclusive company showcase and product listing on our platform to highlight their achievements and future endeavors.